Login | Cas Login
English| 简体中文| 繁体中文

  • Complex
  • Title
  • Keyword
  • Abstract
  • Scholars
  • Journal
  • ISSN
  • Conference
成果搜索

Advanced Search

author：

Zhong, Q. (Zhong, Q..) [1] | Zhang, L. (Zhang, L..) [2] | Wu, L. (Wu, L..) [3] | Zhao, J. (Zhao, J..) [4] | Sun, J. (Sun, J..) [5] | Fang, Y. (Fang, Y..) [6] | Zhou, J. (Zhou, J..) [7] | Chu, Q. (Chu, Q..) [8] | Shen, Y. (Shen, Y..) [9] | Yang, Z. (Yang, Z..) [10] | Chen, L. (Chen, L..) [11] | Huang, M. (Huang, M..) [12] | Lin, X. (Lin, X..) [13] | Liu, Z. (Liu, Z..) [14] | Shen, P. (Shen, P..) [15] | Wang, Z. (Wang, Z..) [16] | Wang, X. (Wang, X..) [17] | Wang, H. (Wang, H..) [18] | Han, C. (Han, C..) [19] | Liu, A. (Liu, A..) [20] | Zhang, H. (Zhang, H..) [21] | Ye, F. (Ye, F..) [22] | Gao, W. (Gao, W..) [23] | Wu, F. (Wu, F..) [24] | Song, Z. (Song, Z..) [25] | Chen, S. (Chen, S..) [26] | Zhou, C. (Zhou, C..) [27] | Huang, D. (Huang, D..) [28] | Zhang, Q. (Zhang, Q..) [29] | Zheng, X. (Zheng, X..) [30] | Miao, Q. (Miao, Q..) [32] | Jiang, K. (Jiang, K..) [33] | Zou, Z. (Zou, Z..) [34] | Xu, Y. (Xu, Y..) [35] | Wu, S. (Wu, S..) [36] | Hong, Y. (Hong, Y..) [38] | Lu, T. (Lu, T..) [39] | Li, C. (Li, C..) [40] | Huang, C. (Huang, C..) [41] | Chen, C. (Chen, C..) [42] | Lin, G. (Lin, G..) [43]

Indexed by：

Scopus

Abstract：

Background:　Tumor　necrosis　(TN)　is　a　common　feature　in　lung　squamous　cell　carcinoma　(LSCC),　which　could　provide　useful　predictive　and　prognostic　information.　Objectives:　This　study　aimed　to　investigate　the　effect　of　pretreatment　pulmonary　TN　(PTN)　on　the　prognosis　of　first-line　anti-programmed　cell　death　1　(PD-1)/PD　ligand　1　(PD-L1)　inhibitor　in　advanced　LSCC.　Design:　We　conducted　a　retrospective　study　to　analyze　the　association　between　the　presence　of　PTN　and　clinical　outcomes　in　advanced　LSCC　patients　treated　with　anti-PD-1/PD-L1　inhibitors.　Methods:　Data　from　240　eligible　patients　were　collected　from　27　hospitals　across　China　between　2016　and　2020.　The　presence　of　PTN　was　assessed　using　contrast-enhanced　chest　computed　tomography　(CT)　imaging　at　baseline.　We　utilized　the　Cox　proportional-hazards　regression　model　to　analyze　the　association　between　PTN　and　clinical　outcomes.　In　addition,　to　account　for　potential　confounding　factors　and　ensure　comparability　between　groups,　we　employed　propensity　score-matching　(PSM)　analysis.　Results:　In　the　overall　patient　cohort,　the　presence　of　PTN　was　39.6%.　The　median　follow-up　duration　was　20.3　months.　The　positive　PTN　group　exhibited　a　notably　inferior　median　progression-free　survival　(PFS;　6.5　months　vs　8.6　months,　p　=　0.012)　compared　to　the　negative　PTN　group.　Within　the　Cox　proportional-hazards　regression　model,　PTN　emerged　as　an　independent　predictor　of　unfavorable　PFS　(hazard　ratio　(HR)　=　1.354,　95%　confidence　interval　(CI):　1.002–1.830,　p　=　0.049).　After　PSM,　the　median　PFS　for　the　positive　PTN　group　(6.5　months　vs　8.0　months,　p　=　0.027)　remained　worse　than　that　of　the　negative　PTN　group.　Multivariate　analyses　also　further　underscored　that　the　presence　of　PTN　independently　posed　a　risk　for　shorter　PFS　(HR　=　1.494,　95%　CI:　1.056–2.112,　p　=　0.023).　However,　no　statistically　significant　difference　in　overall　survival　was　observed　between　the　two　groups.　Conclusion:　Our　study　suggests　that　the　presence　of　PTN　on　baseline　contrast-enhanced　chest　CT　is　a　potential　negative　prognostic　imaging　biomarker　for　the　outcome　of　anti-PD-1/PD-L1　inhibitor　therapy　in　advanced　LSCC.　Further　studies　are　warranted　to　validate　these　findings　and　explore　the　underlying　mechanisms.　©　The　Author(s),　2024.

Keyword：

anti-PD-1/PD-L1 inhibitor lung squamous cell carcinoma prognostic biomarker propensity score-matching pulmonary tumor necrosis

Community：

  • [ 1 ] [Zhong Q.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 2 ] [Zhong Q.]Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China
  • [ 3 ] [Zhong Q.]Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, China
  • [ 4 ] [Zhang L.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 5 ] [Zheng X.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 6 ] [Zheng X.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 7 ] [Miao Q.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 8 ] [Jiang K.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 9 ] [Zou Z.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 10 ] [Xu Y.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 11 ] [Wu S.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 12 ] [Wang H.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 13 ] [Hong Y.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China
  • [ 14 ] [Huang C.]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China

Reprint 's Address：

Email：

Show more details

Related Keywords：

Related Article：

Source ：

Therapeutic Advances in Medical Oncology

ISSN： 1758-8340

Year： 2024

Volume： 16

4 . 3 0 0

JCR@2023

CAS Journal Grade：3

Cited Count：

WoS CC Cited Count：

SCOPUS Cited Count：

ESI Highly Cited Papers on the List： 0 Unfold All

WanFang Cited Count：

Chinese Cited Count：

30 Days PV： 0

Affiliated Colleges：

Get Fulltext

DOI Library Discovery Baidu Scholar Search SCOPUS
Online/Total：174/11231592
Address：FZU Library(No.2 Xuyuan Road, Fuzhou, Fujian, PRC Post Code：350116) Contact Us：0591-22865326
Copyright：FZU Library Technical Support：Beijing Aegean Software Co., Ltd. 闽ICP备05005463号-1